Best Medical Spas

Evolysse™ marks a significant advancement in dermal fillers, introduced by Evolus—the company behind Jeuveau® neurotoxin. Launched in the U.S. in Q2 2025 following FDA approval in February 2025, Evolysse represents the first major technological breakthrough in hyaluronic acid (HA) fillers in over a decade. Developed in partnership with French biomaterial experts Symatese, the Evolysse line utilizes innovative Cold-X™ Technology to preserve the natural structure of HA, delivering smoother integration, reduced swelling, and natural-looking results in dynamic facial areas.

The Innovation: Cold-X™ Technology

Traditional HA fillers use heat during cross-linking, which can degrade the natural HA chains, requiring more cross-linking agent (BDDE) and potentially leading to fragmentation. Cold-X™ performs cross-linking at near-freezing temperatures, preserving longer, more intact HA molecules. This results in a highly efficient gel that integrates seamlessly into tissue, attracts less excess water (reduced post-injection puffiness), and provides durable, natural movement.

Current Products and Indications

As of December 2025, the lineup includes two FDA-approved products:

• Evolysse™ Smooth: A softer gel for mid-to-superficial dermis, ideal for moderate wrinkles and dynamic areas.
• Evolysse™ Form: Firmer for deeper injection, providing structure and lift.

Both are indicated for correcting moderate-to-severe nasolabial folds (NLFs) in adults 22+. Primary treatment sites include smile lines, marionette lines, and perioral areas.

Future expansions: Evolysse™ Sculpt (mid-face volume, FDA submission 2025, expected approval 2026) and Evolysse™ Lips (2027).

Clinical Evidence and Efficacy

Approval was supported by one of the largest HA trial programs (>2,000 patients globally). The pivotal U.S. study was a 140-patient, double-blind, split-face trial vs. Restylane®-L. Evolysse™ Form showed statistical superiority at all 12-month time points; Smooth at 6 and 9 months (despite 20% more control product used). At 6 months, 64-65% of patients reported being less bothered by NLFs. Safety matched Restylane-L: mild-moderate events, no serious treatment-related issues or delayed nodules.

Procedure, Results, and Recovery

Treatment takes 30-60 minutes with topical numbing or lidocaine-containing product. Results appear immediately, with minimal swelling—often “true to form” right away, unlike traditional fillers that may puff initially. Longevity: Up to 12 months in NLFs. Patients praise natural feel during expressions.

Comparison to JUVÉDERM® and Restylane®

Evolysse slots between the softer Vycross® gels (JUVÉDERM®) and firmer NASHA®/XpresHAn™ (Restylane®). It offers less hydrophilicity than many competitors, meaning quicker settling and reduced “overpuffed” appearance. Clinically superior to Restylane-L in trials, with similar versatility but enhanced natural movement.

Safety and Considerations

Reversible with hyaluronidase. Common side effects: bruising, swelling (milder due to technology). Ideal for patients seeking subtlety, especially post-weight loss or in dynamic zones. Always choose experienced injectors.

Evolysse™ is transforming aesthetics in 2025 with its focus on authentic, long-lasting rejuvenation. As the portfolio grows, it positions Evolus as a major player alongside Allergan and Galderma.

Clinical Trial Details for Evolysse™ Form and Evolysse™ Smooth

The FDA approval of Evolysse™ Form and Evolysse™ Smooth (February 2025) was based on a robust clinical program, described as one of the largest for an injectable hyaluronic acid (HA) technology, involving over 2,000 patients globally. The pivotal U.S. study focused on safety and effectiveness for correcting moderate-to-severe nasolabial folds (NLFs).

U.S. Pivotal Study (CLIN2101): Design and Methodology

• Type: Multicenter, double-blind, prospective, randomized, active-controlled, split-face trial.
• Participants: 140 adults (aged 22+) with moderate-to-severe NLFs.
  • 70 patients randomized to Evolysse™ Form.
  • 70 patients randomized to Evolysse™ Smooth.
• Comparator: Restylane®-L (a well-established HA filler).
• Design Notes: Split-face allowed direct head-to-head comparison (Evolysse on one side, Restylane-L on the other). Notably, 20% more Restylane-L was used in the control arm.
• Touch-Ups: Allowed at 2 weeks post-initial treatment for optimal correction.
  • Evolysse™ Form: 73% (51/70) received touch-up.
  • Evolysse™ Smooth: 77% (54/70) received touch-up.
• Primary Endpoint: Non-inferiority in NLF severity improvement at 6 months, assessed by a blinded independent photographic review panel using a validated 5-point Nasolabial Fold Severity Scale.
• Duration: Follow-up over 12 months.
• Assessment: Blinded live evaluators and photographic reviews.

Efficacy Results

Both products met the primary endpoint of non-inferiority and demonstrated statistical superiority over Restylane-L:

• Evolysse™ Form (originally called Lift in pre-approval): Superior at all time points over the full 12 months.
• Evolysse™ Smooth: Superior at 6 and 9 months.
• Patient-Reported Outcomes (at 6 months):
  • 64% less bothered by NLFs when smiling.
  • 65% less bothered by NLFs when relaxed.
• Longevity: Results lasted up to 12 months in most participants (individual variation applies; retreatment typically needed).

Safety Profile

• Comparable to Restylane-L.
• Most adverse events: Mild to moderate (e.g., injection site reactions like swelling, bruising).
• No treatment-related serious adverse events.
• No delayed-onset nodules in Evolysse arms (vs. rare occurrences in some HA fillers).
• Overall favorable, supporting the Cold-X™ technology’s role in reduced complications.

Supporting Data

• European Studies: Additional trials (e.g., CLIN1901) contributed to the global dataset.
• Publication: Full pivotal study results published in the Aesthetic Surgery Journal (May 2025).
• Broader Program: Included diverse patients; aligned with EU MDR approval (as Estyme®).

These trials highlight Evolysse’s advantages in natural integration, reduced swelling, and durability, positioning it as a breakthrough in HA fillers. Always review the full Directions for Use and consult providers for individual suitability.

Jeuveau® Neurotoxin: The Modern Alternative for Frown Lines (2025 Guide)

Jeuveau® (prabotulinumtoxinA-xvfs), often called “Newtox,” is a prescription injectable neurotoxin from Evolus, Inc. FDA-approved in 2019 exclusively for cosmetic use, it temporarily improves moderate to severe glabellar lines (frown lines or “elevens” between the eyebrows) in adults. As of December 2025, Jeuveau has grown rapidly, becoming the fastest-growing neurotoxin in the U.S. for four consecutive years with over 14% market share.

How Jeuveau Works

Like other botulinum toxin type A products, Jeuveau blocks nerve signals to muscles, preventing contractions that cause dynamic wrinkles. It uses Hi-Pure™ technology for high purity (>95%), manufactured in South Korea. Injected intramuscularly into the glabellar area, it relaxes the corrugator and procerus muscles.

Onset, Results, and Duration

Many patients see improvement as early as 2-3 days, with peak effects at 30 days. Results last 3-6 months, often up to 120-180 days in studies. A 2025 JAMA Dermatology study showed Jeuveau with fast onset, strong peak effect (93% strain reduction at Day 30), and superior duration vs. Botox at Day 180.

Procedure and Recovery

Treatment takes 10-20 minutes with fine needles. No downtime—mild redness or bruising possible. Avoid rubbing the area for 24 hours.

Before-and-After Results

Patients achieve smoother, natural-looking frown lines.

Jeuveau vs. Botox

Both use botulinum toxin A, but differences exist:

• Approval — Jeuveau: Glabellar lines only. Botox: Multiple cosmetic (forehead, crow’s feet) and medical uses.
• Onset/Duration — Jeuveau often faster (2-3 days) with comparable or longer duration in some studies.
• Feel — Jeuveau described as “lighter” for natural movement.
• Cost — Jeuveau typically 20-30% cheaper.
• Market — Botox dominant; Jeuveau growing fast for cosmetic-focused patients.

Safety and Side Effects

Common: Bruising, headache, eyelid drooping. Rare serious risks include toxin spread. Contraindicated in allergies or infections.

Jeuveau offers a modern, precise option for frown lines in 2025—ideal for natural, quick results. Consult a qualified injector.

Evolysse™ vs. JUVÉDERM®: A Detailed Comparison (December 2025)

Evolysse™ (Evolus) and JUVÉDERM® (Allergan/AbbVie) are both premium hyaluronic acid (HA) dermal filler lines, but Evolysse represents a newer entrant with innovative manufacturing. Launched in 2025, Evolysse focuses on nasolabial folds (NLFs) and dynamic wrinkles, emphasizing minimal swelling and natural integration via Cold-X™ technology. JUVÉDERM, a market leader for over a decade, offers a broad portfolio powered by Vycross® technology for versatility across facial areas.

Technology Breakdown

• Evolysse Cold-X™: Cross-links HA at near-freezing temperatures, preserving longer native chains with less BDDE and fragmentation. Result: Lower hydrophilicity (less water attraction/post-injection swelling), smoother extrusion, and refined tissue integration.
• JUVÉDERM Vycross®: Blends predominantly low-molecular-weight HA with some high-molecular-weight for efficient cross-linking. Yields smooth, cohesive gels with reduced swelling compared to older lines, but traditional heat processing may cause more chain degradation than Cold-X.

Clinicians note Evolysse feels “sleeker” with controlled lift, while JUVÉDERM offers proven softness and predictability.

Key Comparison Table

Feature	Evolysse™ (Smooth & Form)	JUVÉDERM® (e.g., Vollure, Voluma, Ultra)
Technology	Cold-X™ (cold cross-linking)	Vycross® (low/high MW blend)
Current Indications	Moderate-severe NLFs (smile/laugh lines)	Broad: NLFs, cheeks, lips, chin, temples
Gel Properties	Lower swelling, ultra-smooth integration	Smooth, cohesive; minimal swelling
Longevity	Up to 12 months (NLFs)	12–24 months (varies by product/area)
Best For	Natural results in dynamic folds; minimal puffiness	Versatile volume/lift; established for multiple areas
Clinical Edge	Superior to Restylane-L in trials (less product needed)	Extensive data; high satisfaction across uses
Cost (2025 U.S. Avg./Syringe)	Often lower (aggressive pricing)	$800–$1,500

Results and Clinical Insights

Both provide immediate correction with natural movement. Evolysse excels in reducing “filler fatigue” (overpuffed look) due to less initial swelling—ideal post-weight loss or in visible areas.

Safety is comparable—mild bruising/swelling, reversible with hyaluronidase. Evolysse’s trials showed no serious events.

In 2025, Evolysse challenges JUVÉDERM with innovation and value, especially for NLFs, while JUVÉDERM dominates in breadth. Many providers stock both; choice depends on patient needs and injector preference. Consult a board-certified specialist for tailored advice.